Patents by Inventor Akiko Uetani

Akiko Uetani has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for treating a disease, comprising administering mesenchymal stem cells or culture supernatant thereof to a subject
    Patent number: 11179420
    Abstract: An object of the present invention is to provide novel mesenchymal stem cells demonstrating superior therapeutic effects for various diseases, a novel pharmaceutical composition containing the mesenchymal stem cells, and methods for preparing these. The present invention provides mesenchymal stem cells expressing at least one cell surface marker selected from the group consisting of CD201, CD46, CD56, CD147 and CD165. The mesenchymal stem cells expressing such a specific marker are positive for CD29, CD73, CD90, CD105 and CD166, and maintain an undifferentiated state.
    Type: Grant
    Filed: April 27, 2017
    Date of Patent: November 23, 2021
    Assignee: ROHTO PHARMACEUTICAL CO., LTD.
    Inventors: Yoshifumi Ikeyama, Eiko Uno, Masayo Yumoto, Mihoko Yoshino, Xuan Trung Ngo, Hiroyuki Nishida, Akiko Uetani
  • MESENCHYMAL STEM CELL EXPRESSING AT LEAST ONE CELL SURFACE MARKER SELECTED FROM THE GROUP CONSISTING OF CD201, CD46, CD56, CD147, AND CD165, METHOD FOR PREPARING THE SAME, PHARMACEUTICAL COMPOSITION CONTAINING THE MESENCHYMAL STEM CELLS, AND METHOD FOR PREPARING THE SAME
    Publication number: 20190117701
    Abstract: An object of the present invention is to provide novel mesenchymal stem cells demonstrating superior therapeutic effects for various diseases, a novel pharmaceutical composition containing the mesenchymal stem cells, and methods for preparing these. The present invention provides mesenchymal stem cells expressing at least one cell surface marker selected from the group consisting of CD201, CD46, CD56, CD147 and CD165. The mesenchymal stem cells expressing such a specific marker are positive for CD29, CD73, CD90, CD105 and CD166, and maintain an undifferentiated state.
    Type: Application
    Filed: April 27, 2017
    Publication date: April 25, 2019
    Applicant: ROHTO PHARMACEUTICAL CO., LTD.
    Inventors: Yoshifumi Ikeyama, Eiko Uno, Masayo Yumoto, Mihoko Yoshino, Xuan Trung Ngo, Hiroyuki Nishida, Akiko Uetani